Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Liabilities for 6 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 67.57% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 67.57% year-over-year, with the annual reading at $5.0 million for FY2025, 67.57% down from the prior year.
  • Total Liabilities for Q4 2025 was $5.0 million at Mereo BioPharma, down from $7.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $51.8 million in Q4 2021, with the low at -$54.7 million in Q3 2023.
  • Average Total Liabilities over 5 years is $2.6 million, with a median of $10.8 million recorded in 2024.
  • The sharpest move saw Total Liabilities soared 135.19% in 2024, then crashed 67.57% in 2025.
  • Over 5 years, Total Liabilities stood at $51.8 million in 2021, then plummeted by 49.77% to $26.0 million in 2022, then plummeted by 38.63% to $16.0 million in 2023, then fell by 3.39% to $15.4 million in 2024, then plummeted by 67.57% to $5.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $5.0 million, $7.0 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.